|
|
 |
|
Viewing report
|
|
|
|
Daiichi Sankyo Co., Ltd: PharmaVitae Profile
Datamonitor, Feb 2009, Pages: 148
This analysis examines the historical and forecast performance for Daiichi Sankyo in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Key reasons to purchase this title
- Benchmark Daiichi Sankyos performance against key rivals in the prescription pharmaceutical sector
- Assess the importance of Daiichi Sankyos olmesartan antihypertensives franchise (Benicar, Benicar HCT and Azor) is to the companys outlook
- Evaluate the prospects of the companys key launch product, Effient (prasugrel) which is being co-developed with Eli Lilly
Customers who bought this item also bought
Daiichi Sankyo: PharmaVitae Profile
Daiichi Sankyo: Pipeline, Products, Performance and Potential
Daiichi Sankyo Company Limited
Daiichi Sankyo: PharmaVitae Profile 2005
Daiichi Sankyo Co., Ltd: PharmaVitae Model
Daiichi Sankyo, Ltd. - SWOT Analysis - SWOT Analysis
Daiichi Sankyo Company, Ltd - Financial and Strategic Analysis Review
Daiichi Sankyo Co Ltd Deals Briefing
Daiichi Jitsugyo Company Limited
Daiichi Commodities Company Limited
Daiichi Kensetsu Corp
Daiichi Company Limited
|
|
|
|
